Last updated: July 28, 2026
Cefazolin and Dextrose clinical trials update, market analysis, and 2026–2036 projection
Cefazolin and dextrose is a parenteral, fixed-dose combination that is used clinically as an IV antibiotic regimen where cefazolin is the active antibacterial and dextrose provides the aqueous carrier. Public, drug-level clinical-trials and market datasets for the specific named combination (not cefazolin generics more broadly) are sparse in standard registries and commercial sources, which limits credible, quantifiable forecasting for the product as a standalone asset rather than as “cefazolin injectable” within the broader cefazolin market.
What clinical trials exist for cefazolin and dextrose (NCT status, phase, and endpoints)?
A consolidated, product-specific clinical-trials picture for “cefazolin and dextrose” as a named combination is not available at the level required for a complete, auditable update. Trial records commonly index by active ingredient(s) and dosage form (eg, “cefazolin for injection”) rather than the carrier composition pairing with “dextrose” as a unique proprietary combination.
How are cefazolin and dextrose trials typically indexed in registries?
- Interventional studies: often under cefazolin-only or cefazolin injectable labels, with dextrose carrier details embedded in protocol methods rather than used as a stand-alone search key.
- PK/PD and bioavailability work: carrier composition can vary by site, country, and local preparation practices, so registry titles may omit “dextrose” even when the administered solution contains it.
- Comparative trials: may compare cefazolin dosing regimens or infusion schedules, with the diluent composition stated in methods.
What endpoints are most common in cefazolin IV studies?
- PK endpoints: plasma concentration-time profiles, AUC, Cmax, clearance
- Safety: adverse events, renal markers, hypersensitivity reactions
- Clinical endpoints: surgical site infection rates, bacteremia clearance, microbiologic eradication where applicable
Which indications drive cefazolin injectable use versus cefazolin+dextrose as a carrier combination?
In practice, cefazolin’s use-case is dominated by perioperative prophylaxis and treatment of susceptible bacterial infections. The dextrose component is typically a formulation carrier rather than a therapeutic driver.
Perioperative prophylaxis: the main demand engine
- Orthopedic, general surgery, obstetrics/gynecology, and vascular surgery are typical high-utilization settings for cefazolin prophylaxis.
- Demand correlates with surgical volume and hospital antibiotic stewardship protocols.
Treatment of susceptible infections
- Skin and soft tissue infections, bone and joint infections, respiratory infections, and urinary tract infections are common cefazolin targets when organisms are susceptible.
- Use depends on local antibiogram patterns and formulary positioning versus alternatives (eg, anti-staphylococcal penicillins, vancomycin, or broader cephalosporins).
What patents protect cefazolin and dextrose (composition, method-of-use, formulation)?
For cefazolin injectables, patent landscapes are generally mature and constrained by the fact that cefazolin is an established, off-patent molecule in most markets. The “cefazolin and dextrose” naming does not imply a distinct patentable innovation in itself.
How to interpret the patent question for this combination
- Carrier/formulation details can be covered by old formulation patents, but for cefazolin the baseline compound and many core process routes have long outlived exclusivity.
- Current IP risk is more often associated with specific branded presentation (labeling, manufacturing process, sterility assurance, stability-enhancing excipients, container closure system) rather than the concept “cefazolin + dextrose” at the molecule level.
Data limitation for this specific request
A complete, citation-ready mapping of “patents protecting cefazolin and dextrose” requires a product-identified patent list from authoritative sources (eg, Orange Book and national patent registers matched to the exact marketed NDA/ANDA/strength/container). That product-level patent mapping cannot be produced from the requested topic alone with the level of precision required for litigation, licensing, or investment use.
What is the Orange Book status of cefazolin and dextrose?
A product-specific Orange Book status requires identifying the exact FDA application number (NDA or ANDA), strength, dosage form, and label holder for the named “cefazolin and dextrose” presentation.
Why “cefazolin injectable” vs “cefazolin and dextrose” matters
- The Orange Book typically lists active ingredients, dosage forms, strengths, and the approved application.
- “Dextrose” as a carrier may not create a distinct Orange Book listing if the application is indexed and branded under “cefazolin for injection” with dextrose as part of the solution composition.
Data limitation for this response
No product-identified Orange Book listing can be cited here without the underlying application/labeler match for the named combination.
When does cefazolin and dextrose lose exclusivity (patent expiration and exclusivity timelines)?
For cefazolin injectables, exclusivity and patent terms at the molecule level have largely expired globally. Remaining exclusivity (if any) would typically be presentation- or process-specific at the application level.
What typically governs exclusivity for cefazolin injectables
- New formulation patents tied to stability, concentration, or container closure
- Brand-specific data exclusivity where relevant
- Orphan or pediatric exclusivity is unlikely for a widely used antibiotic but can vary by label history
- Settlement or licensing agreements that delay generic entry by NDA/ANDA-specific factors
Data limitation
A credible loss-of-exclusivity timeline for the specific “cefazolin and dextrose” product cannot be generated without tying to a specific approved application.
Which companies sell cefazolin and dextrose and how does competition look?
The market for cefazolin injectables is highly competitive and dominated by multiple generic manufacturers across major geographies. Competition is typically segmented by:
- strength and dosage form
- package size (vial vs bag)
- supply reliability
- contracting with hospital group purchasing organizations
Competitive dynamics that affect pricing
- Hospital tenders and GPO contracting drive benchmark-based pricing
- Short-term supply constraints can create price spikes
- Availability of sterile manufacturing capacity affects lead times and distributor pricing
Data limitation
A product-specific competitor list for “cefazolin and dextrose” cannot be provided without the exact marketed product identifiers (NDCs and labelers).
What market size does cefazolin (carrier formulation) represent and how large is the dextrose-carrier subsegment?
Cefazolin injectable represents a meaningful portion of the first-generation cephalosporin market. However, the “dextrose-carrier subsegment” usually overlaps with broader cefazolin injectable reporting because carriers are not always broken out in syndicated datasets.
Market projection approach that works for cefazolin
A defensible projection typically models:
- surgical procedure volumes
- antimicrobial formulary penetration for perioperative prophylaxis
- volume growth from population and hospital utilization
- price erosion from generics
- safety stock and supply continuity effects
Data limitation
No reliable, auditable dataset split for “cefazolin and dextrose” as a distinct branded product category is available within the scope of this request.
How does cefazolin and dextrose pricing evolve (generic erosion, tendering, and supply shocks)?
Generic antibiotics pricing is governed by:
- accelerated price erosion after ANDA approvals and contract tender cycles
- margin compression for sterile injectables
- supply disruptions that temporarily shift pricing upward
What matters most to revenue
- Formulary position at large IDN/hospital systems
- Contract term duration and renewal cycles
- Alternative antibiotics substitution when resistance patterns shift
What generic entry risks exist for cefazolin and dextrose (Paragraph IV, 180-day exclusivity, settlement)?
Paragraph IV certifications apply to ANDA filings challenging patents listed in the Orange Book for a reference listed drug. Without a confirmed Orange Book product and patent list, Paragraph IV risk for “cefazolin and dextrose” cannot be stated with the precision required for legal or investment use.
What would normally be checked
- whether any unexpired Orange Book patents exist for the exact product
- whether there are multiple ANDA filers with “first-filer” status
- whether settlements include “pay-for-delay” or delayed launch commitments (where publicly documented)
How does cefazolin and dextrose compare with cefazolin in saline (clinical and formulation differences)?
Carrier differences can affect:
- osmolality and patient fluid considerations
- compatibility and stability in IV preparation
- infusion preparation workflows
Clinical impact
For many patients, the carrier is clinically secondary to cefazolin pharmacology. Switching between dextrose- and saline-based preparations is often driven by:
- hospital formulation availability
- patient-specific fluid restriction or electrolyte concerns
- IV compatibility with other infusions
What manufacturing and IP barriers affect cefazolin and dextrose supply?
Key supply constraints for sterile injectables include:
- aseptic manufacturing throughput
- sterile filtration and sterilization validation
- stability in final container and transport conditions
- container closure system performance
Where delays typically occur
- regulatory inspection findings at sterile fill-finish sites
- raw material sourcing disruptions
- scale-up changes requiring CMC updates
Key Takeaways
- Cefazolin and dextrose functions as a cefazolin injectable presentation where dextrose is a carrier; demand is driven primarily by cefazolin clinical indications, not the carrier.
- Product-specific clinical-trials, Orange Book status, and patent/exclusivity timelines for “cefazolin and dextrose” cannot be compiled into an auditable, complete update without tying to the exact FDA application and marketed presentation identifiers.
- Competitive pressure is structurally high for cefazolin injectables, so revenue outcomes are dominated by contracting, supply continuity, and generic pricing dynamics.
FAQs
- How do I locate the exact FDA listing for “cefazolin and dextrose” (NDC/ANDA/NDA level indexing)?
- Do trials on “cefazolin injectable” cover dextrose-carrier compositions, and how should that affect evidence interpretation?
- Are there formulation patents for cefazolin carrier solutions that survive today, or is IP largely process and presentation-specific?
- What contracting levers most influence hospital purchase prices for cefazolin injectables in the U.S.?
- How do saline-based vs dextrose-based cefazolin presentations affect infusion workflow and patient fluid management protocols?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- ClinicalTrials.gov. Search results for cefazolin injectable studies. (Accessed 2026).
